Biotech

10/28/24

Raven-built Aliada shuttles its potential best-in-class Alzheimer’s treatment to AbbVie

Biotech

Finance

Science

10/18/24

How do you resolve conflict among board members and executives?

Biotech

Culture

10/14/24

The political rot eroding our national health security

Biotech

Policy

09/30/24

What makes a good board chair?

Biotech

Culture

08/16/24

How Jnana picked PKU

Biotech

Culture

Science

08/08/24

What makes a venture round a crossover round?

Biotech

Finance

07/18/24

Semper Maior: Reflecting on a quiet 1H24

Biotech

Finance

06/20/24

When it comes to global drug sales, all revenue is not created equal

Biotech

Culture

Policy

06/12/24

Discount rates and drug value: A Q&A with Josh Cohen

Finance

Policy

Biotech

05/03/24

Join the Quest for GCEA and Affordable Innovation at ISPOR 2024 with No Patient Left Behind

Biotech

Policy

05/02/24

Mariana’s acquisition:RAVen, radiopharmaceuticals, and reflections on company-building

Biotech

Finance

04/25/24

RAVen’s Project Condor fights flu with Cidara deal

Biotech

Finance

Science

04/23/24

Eroding tolerance: A wonder drug shows us the drug industry’s fundamental failure to communicate

Biotech

Culture

Policy

04/15/24

Obvious in hindsight: On financings, pricing uncertainty, and early access to data

Biotech

Finance

03/25/24

Battling the consequences of price controls at high altitude

Biotech

Policy

03/18/24

US biosecurity starts at home, with insurance reform aimed at making innovation affordable

Biotech

Policy

02/29/24

Money talks: Your biotech compensation questions, answered

Biotech

Culture

Finance

02/18/24

New DTC Marketing: Bringing our true customers along on our quest

Biotech

Culture

01/05/24

Semper Maior: Spirits Rising

Biotech

Finance

12/19/23

Rapport’s most popular pieces of 2023

Biotech

Culture